rowatinex 24,8 mg/1 kapsula+ 6,2 mg/1 kapsula+ < 15 mg/1 kapsula+ 3 mg/1 kapsula+ 4 mg/1 kapsula+ 10 mg/1 kapsula+ 4 mg/1 kap
medical intertrade d.o.o. sarajevo - alfa-pinen, anetol, beta-pinen, борнеол, cineol, fenhon, kamfen - želučanootporna kapsula, meka - 24,8 mg/1 kapsula+ 6,2 mg/1 kapsula+ < 15 mg/1 kapsula+ 3 mg/1 kapsula+ 4 mg/1 kapsula+ 10 mg/1 kapsula+ 4 mg/1 kapsula - 1 želučanootporna kapsula, meka sadrži: 24,8 mg alfa pinen, 6,2 mg beta pinen, 15 mg kamfen, 3 mg cineol, 4 mg fenhon, 10 mg borneol, 4 mg anetol
rowachol 13.6 mg/1 kapsula+ 3.4 mg/1 kapsula+ 5 mg/1 kapsula+ 2 mg/1 kapsula+ 6 mg/1 kapsula+ 32 mg/1 kapsula+ 5 mg/1 kapsula že
medical intertrade d.o.o. sarajevo - alfa pinen, beta pinen, borneol, levomentol, kamfen, menton - želučanootporna kapsula, meka - 13.6 mg/1 kapsula+ 3.4 mg/1 kapsula+ 5 mg/1 kapsula+ 2 mg/1 kapsula+ 6 mg/1 kapsula+ 32 mg/1 kapsula+ 5 mg/1 kapsula - 1 želučanootporna kapsula, meka sadrži: 13,6 mg alfa pinen, 3,4 mg beta pinen, 32 mg levomentol, 6 mg menton, 5 mg borneol, 5 mg kamfen, 2 mg cineol
fabrazyme 35 mg/1 viala prašak za koncentrat za otopinu za infuziju
sanofi d.o.o. - agalzidaza beta - prašak za koncentrat za otopinu za infuziju - 35 mg/1 viala - 1 bočica sa praškom za koncentrat za otopinu za infuziju sadrži: 35 mg agalzidaza beta
mircera 120 µg/0.3 ml rastvor za injekciju u napunjenoj šprici
roche d.o.o.roche ltd. - polietilen beta-метокси glikolepoetin - rastvor za injekciju u napunjenoj šprici - 120 µg/0.3 ml - 1 napunjena šprica s 0,3 ml rastvora sadrži: 120 mikrograma metoksi polietilenglikolepoetina beta
mircera 50 µg/0.3 ml otopina za injekciju u napunjenoj štrcaljki
roche d.o.o.roche ltd. - polietilen beta-метокси glikolepoetin - otopina za injekciju u napunjenoj štrcaljki - 50 µg/0.3 ml - 1 napunjena šprica s 0,3 ml otopine sadrži: 50 mikrograma metoksi polietilenglikolepoetina beta
mircera 75 µg/0.3 ml otopina za injekciju u napunjenoj štrcaljki
roche d.o.o.roche ltd. - polietilen beta-метокси glikolepoetin - otopina za injekciju u napunjenoj štrcaljki - 75 µg/0.3 ml - 1 napunjena šprica s 0,3 ml otopine sadrži: 75 mikrograma metoksi polietilenglikolepoetina beta
mircera 100 µg/0.3 ml otopina za injekciju u napunjenoj štrcaljki
roche d.o.o.roche ltd. - polietilen beta-метокси glikolepoetin - otopina za injekciju u napunjenoj štrcaljki - 100 µg/0.3 ml - 1 napunjena šprica s 0,3 ml otopine sadržava 100 mikrograma metoksi polietilenglikolepoetina beta
recormon 2000 i.j./0.3 ml rastvor za injekciju
roche d.o.o.roche ltd. - epoetin beta - rastvor za injekciju - 2000 i.j./0.3 ml - 0,3 ml rastvora za injekciju sadrži: 2000 i.u. epoetin beta (humani rekombinantni eritropoetin)
enteroporc coli ac
ceva santé animale - clostridium perfringens type c, beta1 toxoid / clostridium perfringens, type a, alpha toxoid / clostridium perfringens, type a, beta2 toxoid / escherichia coli, fimbrial adhesin f4ab / escherichia coli, fimbrial adhesin f4ac / escherichia coli, fimbrial adhesin f5 / escherichia coli, fimbrial adhesin f6 - immunologicals for suidae, inactivated bacterial vaccines (including mycoplasma, toxoid and chlamydia) escherichia + clostridium - svinje - for the passive immunisation of progeny by active immunisation of pregnant sows and gilts to reduce:- clinical signs (severe diarrhoea) and mortality caused by escherichia coli strains expressing the fimbrial adhesins f4ab, f4ac, f5 and f6- clinical signs (diarrhoea during the first days of life) associated with clostridium perfringens type a expressing alpha and beta 2 toxins- clinical signs and mortality associated with haemorrhagic and necrotising enteritis caused by clostridium perfringens type c expressing beta1 toxin.
cevenfacta
laboratoire francais du fractionnement et des biotechnologies - eptacog beta (activated) - hemophilia a; hemophilia b - antihemorrhagics - cevenfacta is indicated in adults and adolescents (12 years of age and older) for the treatment of bleeding episodes and for the prevention of bleeding in those undergoing surgery or invasive procedures in the following patient groups:in patients with congenital haemophilia with high-responding inhibitors to coagulation factors viii or ix (i. ≥5 bethesda units (bu)); in patients with congenital haemophilia with low titre inhibitors (bu.